Financials

News Discussions Technicals Seasonals

VBS fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Vectus Biosystems Ltd. is a drug discovery and development company, which engages in the treatment for fibrosis and high blood pressure, which includes therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. Its lead compounds include VB0004, VB4-A32, VB4-A79, and VB4-P5. The company was founded by Karen Duggan on December 12, 2005 and is headquartered in North Ryde, Australia.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

VBS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company